Pfizer And BioNTech Receive Health Canada Authorization For XBB.1.5-Adapted Monovalent COVID-19 Vaccine
Portfolio Pulse from Benzinga Newsdesk
Pfizer Canada ULC and BioNTech SE have received Health Canada authorization for their Omicron XBB.1.5-adapted monovalent COVID-19 vaccine for individuals aged 6 months and older. The updated vaccine will be available in Canada in the coming weeks. The authorization is based on previous clinical, non-clinical, and real-world evidence supporting the safety and efficacy of the Pfizer-BioNTech COVID-19 Vaccines.
September 28, 2023 | 4:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioNTech SE has received Health Canada authorization for its Omicron XBB.1.5-adapted monovalent COVID-19 vaccine, developed in partnership with Pfizer. The vaccine is expected to be available in Canada in the coming weeks.
The news of the Health Canada authorization for BioNTech's updated COVID-19 vaccine is positive and directly relevant to the company. This could potentially increase the company's revenues and positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Pfizer Canada ULC has received Health Canada authorization for its Omicron XBB.1.5-adapted monovalent COVID-19 vaccine, developed in partnership with BioNTech. The vaccine is expected to be available in Canada in the coming weeks.
The news of the Health Canada authorization for Pfizer's updated COVID-19 vaccine is positive and directly relevant to the company. This could potentially increase the company's revenues and positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100